SG11202002994SA - Chimeric antigen receptors that bind to ssea4 and uses thereof - Google Patents

Chimeric antigen receptors that bind to ssea4 and uses thereof

Info

Publication number
SG11202002994SA
SG11202002994SA SG11202002994SA SG11202002994SA SG11202002994SA SG 11202002994S A SG11202002994S A SG 11202002994SA SG 11202002994S A SG11202002994S A SG 11202002994SA SG 11202002994S A SG11202002994S A SG 11202002994SA SG 11202002994S A SG11202002994S A SG 11202002994SA
Authority
SG
Singapore
Prior art keywords
ssea4
bind
chimeric antigen
antigen receptors
receptors
Prior art date
Application number
SG11202002994SA
Inventor
Lan Bo Chen
Original Assignee
Lan Bo Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lan Bo Chen filed Critical Lan Bo Chen
Publication of SG11202002994SA publication Critical patent/SG11202002994SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG11202002994SA 2018-03-20 2019-03-19 Chimeric antigen receptors that bind to ssea4 and uses thereof SG11202002994SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/926,382 US10751399B2 (en) 2018-03-20 2018-03-20 Chimeric antigen receptors that bind to SSEA4 and uses thereof
PCT/US2019/022861 WO2019183025A1 (en) 2018-03-20 2019-03-19 Chimeric antigen receptors that bind to ssea4 and uses thereof

Publications (1)

Publication Number Publication Date
SG11202002994SA true SG11202002994SA (en) 2020-04-29

Family

ID=67984543

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002994SA SG11202002994SA (en) 2018-03-20 2019-03-19 Chimeric antigen receptors that bind to ssea4 and uses thereof

Country Status (12)

Country Link
US (2) US10751399B2 (en)
EP (1) EP3678711A4 (en)
JP (1) JP7378152B2 (en)
KR (1) KR20200135760A (en)
CN (1) CN111629762A (en)
AU (1) AU2019239730A1 (en)
BR (1) BR112020015723A2 (en)
CA (1) CA3078304A1 (en)
IL (1) IL274258B (en)
SG (1) SG11202002994SA (en)
TW (1) TWI817997B (en)
WO (1) WO2019183025A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180665A1 (en) * 2020-03-09 2021-09-16 Janssen Pharmaceutica Nv Compositions and methods for quantifying integration of recombinant vector nucleic acid
TWI817350B (en) * 2021-02-09 2023-10-01 台灣浩鼎生技股份有限公司 Globo series antigens-binding chimeric antigen receptors and uses thereof
WO2022178040A1 (en) * 2021-02-16 2022-08-25 City Of Hope Truncated domain iv egfr and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050828A3 (en) * 2006-06-12 2009-08-26 Oncomethylome Sciences S.A. Methylation markers for early detection and prognosis of colon cancers
IN2012DN00733A (en) * 2009-07-02 2015-06-19 Merz Pharma Gmbh & Co Kgaa
AU2013305838A1 (en) * 2012-08-20 2015-02-26 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI570483B (en) * 2014-07-21 2017-02-11 友達光電股份有限公司 Display device
ES2767399T3 (en) 2014-08-19 2020-06-17 Miltenyi Biotec Bv & Co Kg Chimeric antigen receptor specific for the SSEA4 antigen
CN104673765B (en) * 2014-12-22 2017-11-17 武汉康复得生物科技股份有限公司 One group of great-hearted oxalate oxidase and its application under physiological ph conditions
KR20170093254A (en) 2014-12-29 2017-08-14 노파르티스 아게 Methods for producing chimeric antigen receptor-expressing cells
KR20180121786A (en) * 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 Antibodies, pharmaceutical compositions and methods
US20180028631A1 (en) * 2016-07-29 2018-02-01 Lan Bo Chen Anti-ssea4 chimeric antigen receptors and their use for treating cancer
US20180028633A1 (en) 2016-07-29 2018-02-01 Lan Bo Chen Chimeric antigen receptor combination therapy for treating tumors
KR102528998B1 (en) * 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 Human Antibodies, Pharmaceutical Compositions and Methods
JP7213549B2 (en) * 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use
CN107188968A (en) 2017-05-08 2017-09-22 上海神因生物科技有限公司 A kind of people source Chimeric antigen receptor of targeting PDPN genes and application thereof
CN107759700A (en) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 Target transgenic T cells of CD19 antigens and preparation method and application

Also Published As

Publication number Publication date
CN111629762A (en) 2020-09-04
IL274258A (en) 2020-06-30
EP3678711A4 (en) 2021-06-02
BR112020015723A2 (en) 2020-12-08
US20190290744A1 (en) 2019-09-26
US10751399B2 (en) 2020-08-25
JP7378152B2 (en) 2023-11-13
US20200338177A1 (en) 2020-10-29
US11628210B2 (en) 2023-04-18
EP3678711A1 (en) 2020-07-15
KR20200135760A (en) 2020-12-03
TW202003049A (en) 2020-01-16
AU2019239730A1 (en) 2020-04-23
IL274258B (en) 2022-04-01
CA3078304A1 (en) 2019-09-26
WO2019183025A1 (en) 2019-09-26
TWI817997B (en) 2023-10-11
JP2021517450A (en) 2021-07-26

Similar Documents

Publication Publication Date Title
IL275619A (en) Enhanced chimeric antigen receptors and uses thereof
IL279367A (en) Bcma chimeric antigen receptors and uses thereof
HK1259190A1 (en) Methods and compositions relating to chimeric antigen receptors
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
IL279979A (en) Chimeric antigen receptors with bcma specificity and uses thereof
IL250831A0 (en) Antibodies and chimeric antigen receptors specific for cd19, compositions containing same and uses thereof
IL277078A (en) Anti-cd33 chimeric antigen receptors and their uses
EP3658163A4 (en) Enhanced chimeric antigen receptors and use thereof
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
IL286038A (en) Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
IL277588A (en) Monoclonal antibodies that bind to ssea4 and uses thereof
EP3347474A4 (en) Chimeric antigen receptors and uses thereof
IL287816A (en) Antibody to tigit and use thereof
IL274258B (en) Chimeric antigen receptors that bind to ssea4 and uses thereof
ZA202005837B (en) Cd83-binding chimeric antigen receptors
IL278061A (en) Anti-ror antibody constructs
IL275040A (en) T-cells comprising two different chimeric antigen receptors and uses thereof
ZA202008065B (en) Muc16 specific chimeric antigen receptors and uses thereof
IL286984A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
SG11202103095RA (en) Anti-human vsig4 antibodies and uses thereof
SG11202001011XA (en) Chimeric antigen receptor and car-t cells that bind cxcr5
IL287487A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
GB2585607B (en) Chimeric antigen receptor and application thereof
IL281129A (en) Methods and compositions comprising b7h3 chimeric antigen receptors
SG11202001813UA (en) Polypeptide and antibody bound to polypeptide